Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data will be a wellspring of selectively targeted medicines across many indications.
In a roundtable discussion with BioCentury, 5 AM Ventures Managing Partner Kush Parmar, Flagship Pioneering Venture Partner Paul-Peter Tak and Third Rock Ventures Partner Reid Huber identified targets and tools that could form the basis for new classes of therapies.
Their perspectives point to a near-term future that will see microglia and stromal cells, long dismissed as supporting actors, take center stage as key modulators of disease.
Single cell technologies, once the provenance of individual groups and centers, are going mainstream through international consortia developing shared datasets and analytical tools. The conversation is no longer about whether the methods can deliver actionable insights, but about how to execute on them via multi-targeting therapeutic modalities.
And having all but overtaken oncology, immunology is now poised to have a major impact on neurology, where the cross-talk with innate immunity is yielding new therapeutic strategies for neurodegenerative and autoimmune